The long-acting insulin analogue Detemir (21 days, 40 IU/patient/day) significantly improved memory in patients with Alzheimer’s disease and moderate cognitive deficits [15], but its improving effect with prolonged use (2–4 months) at the same daily dose disappeared [16]. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.